Hepatitis Monthly

Published by: Kowsar

Effects of Pentoxifylline on Non-Alcoholic Steatohepatitis: A Randomized, Double-Blind, Placebo-Controlled Trial in Iran

Nadieh Baniasadi 1 , Faranak Salajegheh 2 , Abbas Pardakhty 3 , Seyed Mehdi Seyedmirzaee 4 , Mohammad Mahdi Hayatbakhsh 5 , Amin Reza Nikpoor 6 and Mojgan Mohammadi 6 , 7 , *
Authors Information
1 Internal Medicine Department, Bam University of Medical Sciences, Bam, IR Iran
2 Department of Gastroenterology, Afzalipour Hospital, Kerman University of Medical Sciences, Kerman, IR Iran
3 Pharmaceutics Research Center, Neuropharmacology Institute, Kerman University of Medical Sciences, Kerman, IR Iran
4 Physiology Research center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, IR Iran
5 Gastroenterology and Hepatology Research Centre, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences, Kerman, IR Iran
6 Department of Immunology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, IR Iran
7 Immunology Research Center, Mashhad University of Medical Sciences, Mashhad, IR Iran
Article information
  • Hepatitis Monthly: November 2015, 15 (11); e58823
  • Published Online: November 28, 2015
  • Article Type: Research Article
  • Received: August 17, 2015
  • Revised: October 2, 2015
  • Accepted: October 7, 2015
  • DOI: 10.5812/hepatmon.33462

To Cite: Baniasadi N, Salajegheh F, Pardakhty A, Seyedmirzaee S M, Hayatbakhsh M M, et al. Effects of Pentoxifylline on Non-Alcoholic Steatohepatitis: A Randomized, Double-Blind, Placebo-Controlled Trial in Iran, Hepat Mon. 2015 ;15(11):e58823. doi: 10.5812/hepatmon.33462.

Copyright: Copyright © 2015, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited..
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Dowman JK, Tomlinson JW, Newsome PN. Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2011; 33(5): 525-40[DOI][PubMed]
  • 2. Peverill W, Powell LW, Skoien R. Evolving concepts in the pathogenesis of NASH: beyond steatosis and inflammation. Int J Mol Sci. 2014; 15(5): 8591-638[DOI][PubMed]
  • 3. Choi S, Diehl AM. Role of inflammation in nonalcoholic steatohepatitis. Curr Opin Gastroenterol. 2005; 21(6): 702-7[PubMed]
  • 4. Targher G, Arcaro G. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis. 2007; 191(2): 235-40[DOI][PubMed]
  • 5. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest. 1995; 95(5): 2409-15[DOI][PubMed]
  • 6. Hotamisligil GS. The role of TNFalpha and TNF receptors in obesity and insulin resistance. J Intern Med. 1999; 245(6): 621-5[PubMed]
  • 7. Muriel P, Fernandez-Martinez E, Perez-Alvarez V, Lara-Ochoa F, Ponce S, Garcia J, et al. Thalidomide ameliorates carbon tetrachloride induced cirrhosis in the rat. Eur J Gastroenterol Hepatol. 2003; 15(9): 951-7[DOI][PubMed]
  • 8. Tilg H, Diehl AM. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med. 2000; 343(20): 1467-76[DOI][PubMed]
  • 9. Lindmark E, Diderholm E, Wallentin L, Siegbahn A. Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. JAMA. 2001; 286(17): 2107-13[PubMed]
  • 10. Marra F, Gastaldelli A, Svegliati Baroni G, Tell G, Tiribelli C. Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. Trends Mol Med. 2008; 14(2): 72-81[DOI][PubMed]
  • 11. Perseghin G, Petersen K, Shulman GI. Cellular mechanism of insulin resistance: potential links with inflammation. Int J Obes Relat Metab Disord. 2003; 27 Suppl 3-11[DOI][PubMed]
  • 12. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest. 2006; 116(7): 1793-801[DOI][PubMed]
  • 13. Jarrar MH, Baranova A, Collantes R, Ranard B, Stepanova M, Bennett C, et al. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2008; 27(5): 412-21[DOI][PubMed]
  • 14. Koppe SW, Sahai A, Malladi P, Whitington PF, Green RM. Pentoxifylline attenuates steatohepatitis induced by the methionine choline deficient diet. J Hepatol. 2004; 41(4): 592-8[DOI][PubMed]
  • 15. Hernandez E, Correa A, Bucio L, Souza V, Kershenobich D, Gutierrez-Ruiz MC. Pentoxifylline diminished acetaldehyde-induced collagen production in hepatic stellate cells by decreasing interleukin-6 expression. Pharmacol Res. 2002; 46(5): 435-43[PubMed]
  • 16. Balibrea JL, Arias-Diaz J, Garcia C, Vara E. Effect of pentoxifylline and somatostatin on tumour necrosis factor production by human pulmonary macrophages. Circ Shock. 1994; 43(2): 51-6[PubMed]
  • 17. Lee YM, Sutedja DS, Wai CT, Dan YY, Aung MO, Zhou L, et al. A randomized controlled pilot study of Pentoxifylline in patients with non-alcoholic steatohepatitis (NASH). Hepatol Int. 2008; 2(2): 196-201[DOI][PubMed]
  • 18. Tuncer İ, Uygan İ, Dülger H, Türkdoğan K, Şekeroğlu MR, Kösem M. The comparative effects of pentoxifylline and ursodeoxycholic acid on IL-1β, Il-6, Il-8 and TNF-α levels in nonalcoholic fatty liver. Eastyern J Med. 2003; 8: 27-32
  • 19. Georgescu EF, Georgescu M. Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study. J Gastrointestin Liver Dis. 2007; 16(1): 39-46[PubMed]
  • 20. Adams LA, Zein CO, Angulo P, Lindor KD. A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. Am J Gastroenterol. 2004; 99(12): 2365-8[DOI][PubMed]
  • 21. Satapathy SK, Sakhuja P, Malhotra V, Sharma BC, Sarin SK. Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol. 2007; 22(5): 634-8[DOI][PubMed]
  • 22. Nonalcoholic steatohepatitis: pathologic features and differential diagnosis. Seminars in diagnostic pathology. : 330-8
  • 23. Yeh MM, Brunt EM. Pathology of nonalcoholic fatty liver disease. Am J Clin Pathol. 2007; 128(5): 837-47[DOI][PubMed]
  • 24. Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology. 2000; 119(6): 1637-48[PubMed]
  • 25. Van Wagner LB, Koppe SW, Brunt EM, Gottstein J, Gardikiotes K, Green RM, et al. Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial. Ann Hepatol. 2011; 10(3): 277-86[PubMed]
  • 26. Buranawui W, Thung-u-thaisri P, Pramoolsinsap C. Pentoxifylline for treatment of non-alcoholic fatty liver disease (NAFLD): a randomized, placebo-controlled study [Abstract s2161]. Gastroenterology A. 2006; 330
  • 27. Zein CO, Yerian LM, Gogate P, Lopez R, Kirwan JP, Feldstein AE, et al. Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. Hepatology. 2011; 54(5): 1610-9[DOI][PubMed]
  • 28. Li W, Zheng L, Sheng C, Cheng X, Qing L, Qu S. Systematic review on the treatment of pentoxifylline in patients with non-alcoholic fatty liver disease. Lipids Health Dis. 2011; 10: 49[DOI][PubMed]
  • 29. Du J, Ma YY, Yu CH, Li YM. Effects of pentoxifylline on nonalcoholic fatty liver disease: a meta-analysis. World J Gastroenterol. 2014; 20(2): 569-77[DOI][PubMed]
  • 30. Jamali R, Dowlatshahi S, Hajatian M. The effect of Pentoxifylline on Liver function tests in Non-alcoholic Fatty Liver Disease Non-diabetic Patients. Govaresh. 2015; 20(2): 90-6
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader